^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    METTL3 (Methyltransferase Like 3)

    i
    Other names: Methyltransferase Like 3, N6-Adenosine-Methyltransferase 70 KDa Subunit, MT-A70, MRNA (2'-O-Methyladenosine-N(6)-)-Methyltransferase, N6-Adenosine-Methyltransferase Catalytic Subunit, Methyltransferase-Like Protein 3, HMETTL3, Spo8, M6A, AdoMet-Binding Subunit Of The Human MRNA (N6-Adenosine)-Methyltransferase, MRNA M(6)A Methyltransferase, METTL3, MTA70, IME4
    Associations

    News

    Trials
    21h
    miR-101/METTL3 axis induces autophagy by interrupting FOXG1/EIF3J-AS1 binding in gliomas. (PubMed, Cell Death Dis)
    Conversely, miR-101-mediated suppression of METTL3 disrupts EIF3J-AS1-FOXG1 binding, restoring MIF expression and promoting autophagy. These findings highlight EIF3J-AS1 and METTL3 as potential therapeutic targets, with disruption of EIF3J-AS1-FOXG1 interactions representing a novel autophagy-modulating strategy for glioma treatment.
    Journal
    |
    MIF (Macrophage Migration Inhibitory Factor) • METTL3 (Methyltransferase Like 3) • FOXG1 (Forkhead Box G1)
    21h
    GATAD2B promotes ovarian cancer malignant progression via MYC/CD47 Axis. (PubMed, Transl Oncol)
    The in vivo and in vitro experiments showed an important role of GATAD2B in OC growth and metastasis, as confirmed by the inhibited tumor growth and the enhanced M1 macrophage infiltration.GATAD2B m6A methylation mediated by METTL3 can promote malignant progress. And GATAD2B can promote immune escape by MYC/CD47 pathway in OC, providing a promising anti-OC therapeutic target.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD47 (CD47 Molecule) • ATAD2 (ATPase Family AAA Domain Containing 2) • METTL3 (Methyltransferase Like 3)
    1d
    EF24 targets METTL3 to reprogram m6A methylation and induce ferroptosis: an epitranscriptomic mechanism with therapeutical potential for glioma. (PubMed, Cell Commun Signal)
    EF24 disrupts this complex through suppressing NRF2 mRNA stability and impairing its protein translation, ultimately depleting GPX4 and triggering ferroptosis cascades. For the first time, our study proposes an epitranscriptomic axis of METTL3/YTHDF1/NRF2/GPX4 as a regulator of ferroptosis in glioma, which may be targeted to design an effective and safe therapeutic strategy.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4) • METTL3 (Methyltransferase Like 3)
    2d
    BE screen reveals METTL3 S2 dephosphorylation sensitizes gastric cancer cells to oxaliplatin by interfering METTL3-eIF3H interaction. (PubMed, Sci Adv)
    In summary, base editor screen provides a versatile approach for exploring the role of phosphorylation sites in cancer chemotherapy. The METTL3-eIF3H interaction may serve as a potential therapeutic target.
    Journal
    |
    BRD4 (Bromodomain Containing 4) • EIF3H (Eukaryotic Translation Initiation Factor 3 Subunit H) • METTL3 (Methyltransferase Like 3)
    |
    oxaliplatin
    4d
    Prognostic potential of N6-methyladenosine methylation-associated genes in lung adenocarcinoma. (PubMed, Transl Cancer Res)
    Our study constructed a novel signature associated with m6A modifications, which can serve as a promising prognostic indicator for LUAD. These findings may provide valuable insights into diagnosis and therapeutic strategies for patients with LUAD.
    Journal
    |
    FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • HNRNPC (Heterogeneous Nuclear Ribonucleoprotein C) • METTL14 (Methyltransferase 14) • METTL3 (Methyltransferase Like 3) • WTAP (WT1 Associated Protein) • YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2) • RBM15 (RNA Binding Motif Protein 15) • VIRMA (Vir Like M6A Methyltransferase Associated) • ZC3H13 (Zinc Finger CCCH-Type Containing 13)
    4d
    Pseudomonas putida KT2440-induced RBM47 regulates non-small cell lung cancer stem cell properties and T cell-mediated antitumor activity. (PubMed, J Thorac Dis)
    Moreover, RBM47 enhanced T-cell proliferation and cytotoxicity by destabilizing the programmed death-ligand 1 (PD-L1) mRNA via 3'-untranslated region (3'-UTR) binding. The RBM47 induction pathway, influenced by KT2440-induced m6A modification, modulates NSCL-CSC properties and T cell-mediated antitumor activity, supporting RBM47 as a novel therapeutic target against LC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • METTL3 (Methyltransferase Like 3) • RBM4 (RNA Binding Motif Protein 4)
    4d
    Targeting Ferroptosis in Nasopharyngeal Carcinoma: Mechanisms, Resistance, and Precision Therapeutic Opportunities. (PubMed, Int J Mol Sci)
    Future directions include biomarker validation, optimization of drug delivery, early-phase clinical trial development, and multidisciplinary collaboration to balance ferroptosis induction in tumors while protecting normal tissues. Collectively, ferroptosis is emerging as both a vulnerability and a therapeutic opportunity for improving outcomes in NPC.
    Review • Journal • IO biomarker
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • HOXA9 (Homeobox A9) • GPX4 (Glutathione Peroxidase 4) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2) • METTL3 (Methyltransferase Like 3)
    4d
    N6-methyladenosine (m6A) of LINC01315 promotes hepatocellular carcinoma progression by activating β-Catentin/WNT pathway. (PubMed, Sci Rep)
    These findings highlight that METTL3-driven LINC01315 accelerates HCC cell propagation, invasion, and migration via the LINC01315/miR-185-5p/β-catenin/WNT signaling axis. LINC01315 could serve as a potent prognostic marker and treatment option in HCC.
    Journal
    |
    miR-185 (MicroRNA 185) • METTL3 (Methyltransferase Like 3)
    5d
    METTL3-mediated m6A modification regulates OSCC progression via the HNRNPA2B1/FOXQ1 axis. (PubMed, Sci Rep)
    METTL3-mediated m6A modification promotes OSCC progression by stabilizing HNRNPA2B1 and FOXQ1 mRNA, driving EMT and malignancy. The METTL3/HNRNPA2B1/FOXQ1 axis is a potential diagnostic and therapeutic target for OSCC, offering novel insights into epigenetic regulation and treatment strategies.
    Journal
    |
    HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) • METTL3 (Methyltransferase Like 3)
    6d
    N6-Methyladenosine: an RNA modification as a central regulator of cancer. (PubMed, Nat Rev Cancer)
    METTL3 inhibitors not only disrupt m6A-dependent pathways but also elevate double-stranded RNA levels, activating innate immune responses and antitumour immunity. We emphasize the need for high-resolution quantitative m6A mapping in cancer and mechanistic studies to better understand the specific transcripts that exhibit altered patterns of m6A in cancer and to identify patient subgroups most likely to benefit from METTL3 inhibitors.
    Review • Journal
    |
    METTL3 (Methyltransferase Like 3)
    6d
    Downregulated Smad3 signaling impairs the maturation of MO-MDSC in colorectal cancer. (PubMed, Cell Death Dis)
    Clinically, plasma Tgfβ1 levels correlate with the MO-MDSC/PMN-MDSC ratio across cancer types, highlighting its biomarker potential. Our findings unveil Smad3 as a critical regulator of MDSC fate and propose novel therapeutic targets for tumor immunotherapy.
    Journal • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1) • METTL3 (Methyltransferase Like 3) • SMAD3 (SMAD Family Member 3)